Drugs / [F-18]-FAPI-74
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06413355 | Jul 2024 → Jul 2027 expected | — | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]-FAPI-74 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06413355 ↗ |
| Action | Inhibit | “radiolabeled FAP inhibitor” NCT06413355 ↗ |
| Modality | Diagnostic / imaging agent | “A positron-emitting radiopharmaceutical” NCT06413355 ↗ |